Topical and systemic active ingredients: proven and new therapeutic approaches

Several risk factors and triggers are known to contribute to the different clinical manifestations of rosacea by activating or modulating neurovascular or immunological processes. Thanks to advances in research into the factors involved in the pathogenesis, the complexity of the disease is increasingly better understood at the molecular level. This is also reflected in the availability of Phase III data on several drug candidates for rosacea. Some of these innovative active substances have now been approved in the USA.